Induced Pluripotent Stem Cell (iPS Cells) - Content Archive

Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy

November 30, 2018 By Cade Hildreth (CEO)

Company to Initiate First-ever U.S. Clinical Investigation of iPSC-derived Cell Product

FT500 to be Featured in Oral Presentation on Monday, December 3 at ASH Annual Meeting

SAN DIEGO, Nov. 30, 2018 — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. [Read more…]

Evotec to Pair Its iPSC Platform for Drug Discovery with Immuneering’s AI Technology

November 29, 2018 By Cade Hildreth (CEO)

Induced pluripotent stem cells are a type of pluripotent stem cell that can be created from differentiated (“adult”) cells. iPSCs are increasingly being explored for applications within drug development and discovery. This is because patient-derived somatic cells (for example, fibroblasts) can be reprogrammed to produce iPSCs that have disease-specific genetic aberrations. These cells can then be differentiated into the disease-affected cell type (for example, neurons in neurodegenerative diseases). [Read more…]

SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy

November 28, 2018 By Cade Hildreth (CEO)

GERMANTOWN, Md., Nov. 12, 2018 — SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes.

An analysis of islet transplant trials registered on clinicaltrials.gov was conducted with the goal of extracting insights to apply in the study design of SERAXIS lead candidate, SR-01 for the treatment of type 1 diabetes. The results of this analysis were published this week in Stem Cells Translational Medicine (doi:10.1002/sctm.18-0156). SR-01 is a combination therapy of insulin-producing cells encapsulated in the retrievable biocompatible SeraGraft^TM device, designed to prevent immune system access to the cells after implantation. [Read more…]

iPS Cell Market Poised for Burgeoning Growth

November 20, 2018 By Cade Hildreth (CEO)

Recent years have seen major advances in the clinical applications of iPSCs, with Cynata Therapeutics progressing the world’s first formal trial of an iPSC-derived cell therapeutic and demonstrating that CYP-001, its lead iPSC-derived mesenchymal stem cell (MSC) product candidate, met all safety and efficacy endpoints in its Phase 1 trial for GvHD.

With multiple physician-led iPSC studies also underway in Japan for applications ranging from Parkinson’s disease to heart disease, the iPSC market is poised to for burgeoning growth. There has also been dramatic progress with production and differentiation technologies related to iPSCs, as well as growing use of iPSCs within drug discovery, disease modelling, tissue engineering, and precision medicine. [Read more…]

ORIG3N, Producing Patient-Specific iPS Cells – Interview with Robin Smith, CEO

November 12, 2018 By Cade Hildreth (CEO)

ORIG3N, a biotechnology start-up headquartered in Boston, is attracting global attention for several reasons. First, it has created the world’s largest blood cell repository. ORIG3N is using these blood cells to produce patient-specific induced pluripotent stem cells (iPSCs), allowing the cells to be ever-renewing and giving rise to a living database of humanity known as LifeCapsule.

Second, the company has two other business segments, called LifeProfile and LifeSystems. These business units of ORIG3N help people to better understand the links between their genes and how their minds and bodies work.

Third, ORIG3N has identified HLA Superdonor matches for 90% of the U.S. population, positioning it to be custodians of this “first of a kind asset on planet earth.”

[Read more…]